Instituto Nacional de Cancerologia, Columbia
14
0
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
14.3%
2 terminated/withdrawn out of 14 trials
71.4%
-15.1% vs industry average
7%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R
Role: collaborator
Effectiveness of Interventions for Improving HPV Vaccination Cover
Role: lead
Quality of Life as a Predictor of OS and PFS in Patients With Lung Cancer
Role: lead
ECO-LEAK Technique: Early Detection of Colorectal Anastomotic Leakage by Transvaginal Ultrasound
Role: collaborator
Curcumin in Advanced Cervical Cancer
Role: lead
Human Papilloma Virus (HPV) Self-collection and Women Adherence
Role: lead
Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer
Role: lead
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate
Role: lead
Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study
Role: lead
Efficacy and Safety of a Preoperative Aerobic Exercise Program in Patients With Gastrointestinal Cancer.
Role: lead
Chemotherapy / Radiotherapy in Uterine Cervical Neoplasms
Role: lead
ROLL vs WGLL for Non-palpable Breast Lesions
Role: lead
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
Role: lead
Resource-Sparing Curative Treatment for Rectal Cancer
Role: collaborator
All 14 trials loaded